Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl

摘要: An impairment of the monoaminergic systems has frequently been reported for Alzheimer's disease (AD) as well an overactivity cerebral monoamineoxidase B (MAO-B). L-deprenyl (LD), a selective and irreversible MAO-B inhibitor, recently proposed treatment AD. The cerebrospinal fluid (CSF) levels norepinephrine (NE), epinephrine (E), dopamine (DA), 3-methoxy-4-hydroxyphenylglycol (MHPG), 5-hydroxyindoleacetic acid (5-HIAA), homovanillic (HVA) were studied in 14 patients suffering from dementia Alzheimer type (DAT) controls. A three-month double-blind study comparing LD with placebo was carried out, DAT group, influence on neurotransmitter cognitive performance evaluated. basal revealed significant reduction CSF NE HVA when compared controls; determined decrease only and, to neuropsychological investigation, global amelioration performances.